Matthew O'Brien
Stock Analyst at Piper Sandler
(1.65)
# 2,197
Out of 4,479 analysts
22
Total ratings
68.75%
Success rate
8.96%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $140 → $115 | $106.27 | +8.21% | 12 | Jul 1, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $17 | $9.90 | +71.72% | 2 | May 8, 2024 | |
| PODD Insulet | Maintains: Neutral | $295 → $230 | $197.19 | +16.64% | 1 | Feb 24, 2022 | |
| KRMD KORU Medical Systems | Downgrades: Neutral | n/a | $2.27 | - | 1 | Jan 26, 2021 | |
| IART Integra LifeSciences Holdings | Downgrades: Neutral | n/a | $29.19 | - | 1 | Jan 7, 2020 | |
| BAX Baxter International | Maintains: Overweight | n/a | $32.85 | - | 1 | Jul 27, 2018 | |
| ALGN Align Technology | Maintains: Overweight | n/a | $239.74 | - | 1 | May 24, 2018 | |
| MOTS Motus GI Holdings | Initiates: Overweight | $2,100 | $0.04 | +4,952,730.19% | 1 | Mar 12, 2018 | |
| DXCM DexCom | Reinstates: Overweight | n/a | $112.49 | - | 1 | May 22, 2017 | |
| MDXG MiMedx Group | Initiates: Overweight | n/a | $6.78 | - | 1 | Mar 3, 2017 |
Zimmer Biomet Holdings
Jul 1, 2024
Downgrades: Neutral
Price Target: $140 → $115
Current: $106.27
Upside: +8.21%
Alphatec Holdings
May 8, 2024
Maintains: Overweight
Price Target: $19 → $17
Current: $9.90
Upside: +71.72%
Insulet
Feb 24, 2022
Maintains: Neutral
Price Target: $295 → $230
Current: $197.19
Upside: +16.64%
KORU Medical Systems
Jan 26, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.27
Upside: -
Integra LifeSciences Holdings
Jan 7, 2020
Downgrades: Neutral
Price Target: n/a
Current: $29.19
Upside: -
Baxter International
Jul 27, 2018
Maintains: Overweight
Price Target: n/a
Current: $32.85
Upside: -
Align Technology
May 24, 2018
Maintains: Overweight
Price Target: n/a
Current: $239.74
Upside: -
Motus GI Holdings
Mar 12, 2018
Initiates: Overweight
Price Target: $2,100
Current: $0.04
Upside: +4,952,730.19%
DexCom
May 22, 2017
Reinstates: Overweight
Price Target: n/a
Current: $112.49
Upside: -
MiMedx Group
Mar 3, 2017
Initiates: Overweight
Price Target: n/a
Current: $6.78
Upside: -